TR201907942T4 - Aktif bir bileşen olarak takrolimus içeren sürekli salımlı peletler. - Google Patents

Aktif bir bileşen olarak takrolimus içeren sürekli salımlı peletler. Download PDF

Info

Publication number
TR201907942T4
TR201907942T4 TR2019/07942T TR201907942T TR201907942T4 TR 201907942 T4 TR201907942 T4 TR 201907942T4 TR 2019/07942 T TR2019/07942 T TR 2019/07942T TR 201907942 T TR201907942 T TR 201907942T TR 201907942 T4 TR201907942 T4 TR 201907942T4
Authority
TR
Turkey
Prior art keywords
release pellets
sustained release
present
active ingredient
pellets
Prior art date
Application number
TR2019/07942T
Other languages
English (en)
Inventor
Lee Hee-Yub
Original Assignee
Hee Yub Lee
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hee Yub Lee filed Critical Hee Yub Lee
Publication of TR201907942T4 publication Critical patent/TR201907942T4/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Mevcut buluş, aktif bir bileşen olarak takrolimus içeren sürekli salımlı peletler ile ilgilidir. Bu buluşun sürekli salımlı peletleri birden fazla hidroksipropil metilselüloz katmanına sahiptir ve ilaçların salımını, belirli hidroksipropil metilselüloz ve Surelease ¢ içerikleri ile kontrol edebilir, böylece çözünme hızını homojen ve kararlı hale getirir ve çözünme hızının arzu edildiği şekilde ayarlanmasını sağlar. Mevcut buluşun peletlerinin hazırlanmasına yönelik işlemin tamamı, tek bir akışkan yataklı granülatörde gerçekleştirilir ve bu nedenle hazırlama işlemi basitleştirilir ve homojen partikül büyüklüğü dağılımına ve içeriğine sahip sürekli salımlı peletler elde edilirken hazırlama işlemine yönelik gereken süre kısaltılır. Mevcut buluşa ait sürekli salımlı peletler, 24 saate kadar süren tıbbi etkilere sahip olabilir ve bu nedenle, günde sadece bir kez uygulanabilir ve böylece hastanın uyumunu geliştirir.
TR2019/07942T 2010-10-19 2011-10-17 Aktif bir bileşen olarak takrolimus içeren sürekli salımlı peletler. TR201907942T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020100101778A KR101243938B1 (ko) 2010-10-19 2010-10-19 타크롤리무스를 유효성분으로 함유하는 서방형 펠렛

Publications (1)

Publication Number Publication Date
TR201907942T4 true TR201907942T4 (tr) 2019-06-21

Family

ID=45975704

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/07942T TR201907942T4 (tr) 2010-10-19 2011-10-17 Aktif bir bileşen olarak takrolimus içeren sürekli salımlı peletler.

Country Status (7)

Country Link
US (1) US9358210B2 (tr)
EP (1) EP2630956B8 (tr)
KR (1) KR101243938B1 (tr)
CN (1) CN103189054B (tr)
ES (1) ES2727594T3 (tr)
TR (1) TR201907942T4 (tr)
WO (1) WO2012053785A2 (tr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9607412B2 (en) * 2010-02-04 2017-03-28 Ciena Corporation Method for rapid determination of lowest cost wavelength routes through a photonic network based on pre-validated paths
CN103432099A (zh) * 2013-08-13 2013-12-11 江苏正大清江制药有限公司 一种他克莫司缓释胶囊及其制备方法
WO2015153984A2 (en) 2014-04-04 2015-10-08 Pharmaquest International Center, LLC Disintegrating monolithic modified release tablets containing quadri-layer extended release granules
US20170072058A1 (en) 2014-11-21 2017-03-16 Solipharma Llc Pharmaceutical composition containing tacrolimus and preparation methods thereof
CN104473907A (zh) * 2014-12-25 2015-04-01 北京华禧联合科技发展有限公司 一种他克莫司的口服缓释制剂
CN114222561A (zh) * 2019-06-03 2022-03-22 合成生物制品有限公司 碱性磷酸酶制剂及其用途
JP7361004B2 (ja) * 2020-09-08 2023-10-13 信越化学工業株式会社 アルコール組成物の製造方法
CN112641733B (zh) * 2020-12-30 2022-11-22 北京华氏开元医药科技有限公司 一种西罗莫司缓释微丸及其制备方法
CN116650444B (zh) * 2023-07-31 2023-10-31 国药集团川抗制药有限公司 一种他克莫司缓释药物及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8608080D0 (en) * 1986-04-02 1986-05-08 Fujisawa Pharmaceutical Co Solid dispersion composition
US5395626A (en) * 1994-03-23 1995-03-07 Ortho Pharmaceutical Corporation Multilayered controlled release pharmaceutical dosage form
KR100539706B1 (ko) * 2005-01-25 2005-12-28 지엘팜텍 주식회사 타크로리무스 및 장용성 고분자를 함유하는 고체분산체
EP2067475A4 (en) * 2006-09-26 2010-12-15 Astellas Pharma Inc PREPARATION FOR TACROLIMUS MAINTAINED RELEASE
EP2119442A4 (en) * 2006-12-28 2010-12-15 Astellas Pharma Inc PHARMACEUTICAL COMPOSITION WITH TACROLIMUS MAINTAINED RELEASE
JP2010522742A (ja) * 2007-03-29 2010-07-08 パナセア バイオテック リミテッド タクロリムスの修飾型剤形
US8110226B2 (en) * 2007-07-20 2012-02-07 Mylan Pharmaceuticals Inc. Drug formulations having inert sealed cores
KR101174183B1 (ko) * 2008-11-28 2012-08-16 주식회사 삼양바이오팜 생체이용률이 향상된 타크로리무스 제제 및 상기 제제의 제조방법
CN101664394A (zh) * 2009-09-25 2010-03-10 宋洪涛 他克莫司缓控释制剂及其制备方法

Also Published As

Publication number Publication date
EP2630956A2 (en) 2013-08-28
CN103189054B (zh) 2016-06-01
CN103189054A (zh) 2013-07-03
EP2630956B1 (en) 2019-02-27
US20130216624A1 (en) 2013-08-22
US9358210B2 (en) 2016-06-07
KR20120047339A (ko) 2012-05-14
ES2727594T3 (es) 2019-10-17
KR101243938B1 (ko) 2013-03-19
EP2630956B8 (en) 2019-07-17
WO2012053785A2 (ko) 2012-04-26
WO2012053785A3 (ko) 2012-06-28
EP2630956A4 (en) 2016-08-03

Similar Documents

Publication Publication Date Title
TR201907942T4 (tr) Aktif bir bileşen olarak takrolimus içeren sürekli salımlı peletler.
PH12015502134A1 (en) Mosapride sustained-release preparation for providing pharmacological and clinical effects with once-a-day administration
TWI538700B (zh) 伊伐佈雷定或其可藥用鹽的緩釋製劑
CN106924208A (zh) 一种复方达格列净二甲双胍缓释片及其制备方法
CN102218042A (zh) 富马酸喹硫平组合物的缓释片剂及其制备方法
GB2482432A (en) Stable pharmaceutical composition for atherosclerosis
EP2606879A1 (en) Multiple unit pellet tablet formulation comprising an opioid
HRP20200642T1 (hr) Čvrsti obrazac za doziranje koji sadrži mikronizirani citizin
KR20160000762A (ko) 에제티미브 및 로수바스타틴을 포함하는 경구용 복합제제 및 그 제조방법
ES2663357T3 (es) Formulaciones de mazindol
CN106983726B (zh) 阿齐沙坦片及其制备方法
JP6880000B2 (ja) 有効成分の化学的安定性に優れたフィルムコーティング錠
MX2017005163A (es) Composiciones de liberación prolongada de onapristona y métodos.
TR202016210A2 (tr) Asidik madde içeren farmasötik form
CN103585357B (zh) 裸花紫珠缓释微丸及其制备方法和应用
CN103690505B (zh) 一种安眠类双层控释片及其制备方法
WO2011014009A3 (ko) 신규 이치환된 페녹시아세틸계 화합물 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 다약제내성 억제용 약학적 조성물
CN101658507B (zh) 一种愈创木酚甘油醚和伪麻黄碱的复方缓释制剂
JP5755382B2 (ja) 口腔内崩壊錠
CN104225596A (zh) 一种治疗胃炎及胃溃疡的药物组合物
Pandya et al. Optimization and evaluation of a formulation Containing Low Soluble Antihypertensive agent
ES2582878T3 (es) Formulación farmacéutica que comprende una combinación de un relajante muscular y un analgésico
JP2015027981A (ja) 腸溶性細粒及び医薬組成物
CN104367562A (zh) 盐酸普拉克索缓释片及制备方法
WO2012068076A3 (en) Pharmaceutical formulations containing soluble drugs